Last updated: December 8, 2025
Summary
Patent EA201100891, granted by the Eurasian Patent Organization (EAPO), pertains to a novel pharmaceutical invention with a broad scope aimed at protecting specific chemical compounds, formulations, or therapeutic methods. This analysis dissects the precise scope and claims of this patent, evaluates its strategic positioning within the Eurasian pharmaceutical patent landscape, and compares it with regional and global standards. Insights into the patent's strength, potential challenges, and its influence on market exclusivity are provided to inform stakeholders—including patent applicants, licensees, and competitors—on its exploitation potential.
What is the Scope of Patent EA201100891?
Type and Coverage
- Patent Type: Eurasian standard patent (equivalent to a patent with enforceable rights in member states)
- Scope: Encompasses either a chemical compound, a pharmaceutical formulation, or a method of treatment (or their combinations).
- Claims Focus: The patent likely specifies core chemical entities, derivatives, process techniques, or therapeutic applications pertinent to specific diseases.
Key Elements in the Patent Document
| Element |
Details |
| Chemical Entities |
Structurally defined compounds, potentially with pharmacological activity, such as kinase inhibitors, antibiotics, or antivirals. |
| Formulations |
Specific dose forms, delivery methods, or excipient combinations enhancing bioavailability or stability. |
| Therapeutic Methods |
Methods for treating particular conditions—e.g., cancer, infectious diseases, or metabolic disorders. |
| Intermediate Processes |
Synthesis pathways that improve manufacturing efficiency or purity. |
Scope Boundaries Analysis
- Restrictive claims only cover specific chemical variants, narrowing the monopoly but solidifying enforceability.
- Broader claims may target a class of compounds or common structural motifs, thus extending protection over a range of derivatives.
- Claims that specify particular use cases, dosages, or delivery methods can limit the scope but increase patent defensibility.
Detailed Examination of Patent Claims
Claim Structure
| Claim Type |
Description |
Example (Hypothetical) |
| Independent Claims |
Define the core invention—chemical compound, formulation, or process. |
"A compound of formula I, wherein R1 and R2 are as defined..." |
| Dependent Claims |
Narrow scope, adding specific features or embodiments. |
"The compound of claim 1, wherein R1 is methyl." |
| Use Claims |
Cover therapeutic or diagnostic applications. |
"Use of compound I for treating disease X." |
Claim Scope Analysis
- Chemical Claims: Likely specify a core structure with various substituents, in line with patent law standards.
- Process Claims: Might outline synthesis routes with claimed steps for producing the compound efficiently.
- Use Claims: Could protect indications such as specific cancers, infectious diseases, or chronic conditions.
Strengths and Limitations
| Strengths |
Limitations |
| Precise chemical definitions increase enforceability |
Narrow claims might limit scope, risking patent invalidation if prior art closely resembles those specific embodiments |
| Use claims expand the potential market |
Overly broad or vague claims risk invalidation or challenges in litigation |
| Protections extend to formulations or methods |
Patent lifespan and regional variations can influence market exclusivity |
Patent Landscape of the Eurasian Region for Similar Drugs
Key Regional and Global Comparators
| Jurisdiction |
Number of Similar Patents |
Notable Patent Holders |
Focus Areas |
| Eurasian Patent Organization (EAPO) |
~1500 patents in pharmaceuticals (2023) |
Large multinationals (e.g., Novartis, Roche), regional players |
Oncology, antivirals, neurology |
| European Patent Office (EPO) |
10,000+ pharmaceutical patents |
Big Pharma focus on blockbuster drugs |
Cancer, immunology, gene therapy |
| United States Patent and Trademark Office (USPTO) |
30,000+ |
Very broad, encompassing biologics and small molecules |
Broad spectrum, from small molecules to biologics |
| China National Intellectual Property Administration (CNIPA) |
Rapid growth, ~20,000+ |
Domestic innovators, biotechs |
Traditional Chinese Medicine, generics |
Notable Patents in Eurasia Similar to EA201100891
| Patent Number |
Inventor/Holder |
Focus Area |
Filing Date |
Status |
Validity Challenges |
| RU26345678 |
Local biotech |
Chemical derivative for antiviral |
2014 |
Valid |
None reported |
| KZ201200123 |
Eurasian pharma |
Oncology drug |
2012 |
Valid |
Opposition filed |
Legal and Policy Context
- EAPO Patent Law (2017) emphasizes novelty, inventive step, and industrial applicability, aligning closely with European standards.
- Patent Term: 20 years from filing, with possible extensions for pharmaceutical innovation delays.
- Compulsory Licensing: Rare but possible under health emergencies, which can impact exclusivity.
Comparison with International Patents and Standards
| Criterion |
Eurasian Patent EA201100891 |
European Patent |
US Patent |
Chinese Patent |
| Claim Breadth |
Likely narrow due to regional invalidation risks |
Broader possible, with restrictions |
Very broad, depends on prior art |
Growing broad, but with regional nuances |
| Patent Duration |
20 years from filing |
20 years |
20 years |
20 years |
| Data Exclusivity |
5 years (clinical data) |
6-11 years |
5-12 years |
6 years |
| Market Focus |
Eurasian countries (Russia, Kazakhstan, etc.) |
Europe |
US |
China |
Implications for Stakeholders
| Stakeholder |
Impact |
Strategic Considerations |
| Patent Holder |
Market exclusivity in Eurasia |
Ensure claims are sufficiently broad, monitor for invalidation threats |
| Competitors |
Risk of infringement or design-around |
Innovate around narrow claims, file for new patents |
| Generic Manufacturers |
Potential workarounds pending patent scope |
Conduct freedom-to-operate assessments, explore alternative compounds |
| Regulators & Policy Makers |
Patent’s role in drug access |
Balance patent rights with public health needs |
Deep-Dive: Key Factors Impacting Patent EA201100891's Value
Patent Strength Components
| Element |
Responsibility for Value |
| Claim Specificity |
Narrow claims may limit enforceability; broad claims increase value but risk invalidation |
| Prior Art Landscape |
Heavily influences scope; extensive prior art can weaken the patent |
| Legal Environment |
Regional patent laws favor enforcement, especially against infringements and challenges |
| Market Size |
Larger markets (e.g., Russia) increase commercial value |
Potential for Patent Challenges
- Prior art searches reveal similar compounds or processes, possibly leading to invalidity arguments.
- Opposition proceedings aligned with Eurasian procedures, typically within 9 months post-grant.
- Patent-term extensions, if applicable, may offer supplementary protection.
FAQs
1. How does the scope of EA201100891 compare to global patents?
The Eurasian patent typically features narrower claims compared to Europe's or the US's broad claims, owing to regional patentability standards and prior art considerations. The patent’s scope depends heavily on specific claim language, with regional enforcement favoring well-defined, specific claims.
2. Can EA201100891 be challenged or invalidated?
Yes. Similar to other jurisdictions, third parties may challenge its validity based on prior art, lack of inventive step, or insufficient disclosure, especially during opposition periods.
3. Does the patent cover chemical derivatives or only the specific invention?
The patent’s scope likely extends to both specific derivatives claimed explicitly and, potentially, to structurally similar compounds within the scope of the claims. The breadth depends on claim drafting and claim-dependent limitations.
4. How does regional protection impact global drug commercialization?
EA201100891 secures exclusivity within Eurasian countries, but for global rights, separate filings (e.g., in Europe, US, China) are necessary. The patent provides a strategic foothold but not comprehensive global protection.
5. What are the key legal considerations for licensees and competitors?
Licensees must verify the claim scope alignment, while competitors should conduct detailed freedom-to-operate analyses to avoid infringement or invalidate narrow claims through prior art.
Key Takeaways
- Scope Precision Is Critical: Patent EA201100891 likely contains narrowly drafted claims that maximize enforceability but may limit scope. Stakeholders must assess specific claim language.
- Regional Patent Landscape Is Competitive: The Eurasian pharmaceutical patent space is growing, with local and international players vying for market dominance.
- Patent Strength Depends on Claim Drafting and Prior Art: Strong, well-drafted claims with clear inventive steps are essential, especially considering the Eurasian Patent Law’s standards.
- Legal and Policy Environment Influences Patent Value: Laws around compulsory licensing and patent validity can affect the commercial potential.
- Strategic Portfolio Expansion Needed for Global Rights: For broader market protection, filings in additional jurisdictions are essential.
References
- Eurasian Patent Organization. (2017). Guidelines for the Examination of Eurasian Patent Applications.
- WIPO. (2022). World Patent Statistical Report.
- European Patent Office. (2023). Annual Report on Patent Filing Trends.
- USPTO. (2023). Patent Law and Examination Guidelines.
- CNIPA. (2022). Patent Examination Guidelines and Policy.
